Gyre Therapeutics Q3 2026 Earnings Date & Estimates

Gyre Therapeutics (NASDAQ:GYRE) is a biopharmaceutical company focused on developing therapies for fibrotic diseases, with an emphasis on liver fibrosis and other serious chronic conditions. The company’s research and development activities are centered on novel small-molecule treatments intended to address the underlying processes that cause excessive scar tissue formation.

Gyre’s lead investigational product is F351, also known as hydronidone, a potential treatment for liver fibrosis. The therapy has been studied in China for hepatitis B virus-associated liver fibrosis and is also being evaluated in the United States for liver fibrosis associated with nonalcoholic steatohepatitis. F351 remains an investigational product and has not been established as safe or effective for any indication by regulatory authorities.

The company has operations and development activities spanning the United States and China. Gyre adopted its current name after completing a business combination with Beijing Continent Pharmaceuticals in 2023; before that transaction, the U.S. public company operated as Catalyst Biosciences. Through its relationship with the China-based business, Gyre has access to additional development, regulatory and commercialization capabilities in the Chinese market.